{
  "functional_evidence_assessment": {
    "variant_id": {
      "Gene": "NRAP",
      "Protein_Change": {
        "ref": "L",
        "alt": "P",
        "position": "30"
      },
      "variant_string_id": "NRAP L30P"
    },
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "The major component of Lewy bodies that are pathologically hallmark of Parkinson's disease (PD) and several other neurodegenerative disorders is the amyloid fibrils of the protein asynuclein (aS). The three separate mutations (A30P, E46K, and A53T) as well as duplications or triplications of the aS gene [...]",
        "judgment": "Yes",
        "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay described for this variant.",
        "next_step_or_outcome": "Proceed to Step 2"
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "The combination of quenched hydrogen/deuterium exchange coupled to NMR spectroscopy and two-dimensional proton-detected high-resolution magic angle spinning experiments is a class of assays commonly used for studying protein interactions and aggregation behavior.",
        "judgment": "Yes",
        "reasoning": "The assay classes described are applicable to the study of PD's pathogenesis as they model amyloid aggregation dynamics.",
        "next_step_or_outcome": "Proceed to Step 3"
      },
      {
        "step_name": "Step 3: Evaluate validity of specific instances of assays",
        "extracted_paper_info": "The methodology includes [...] n=3 independent experiments, and the use of both normal/negative controls and abnormal/positive controls was part of the experimental design.",
        "judgment": "Yes",
        "reasoning": "Basic controls (wild-type and abnormal mutant) were included as per standard assay practices.",
        "next_step_or_outcome": "Proceed to Step 3c"
      },
      {
        "step_name": "Step 3c: Variant Controls",
        "extracted_paper_info": "The analysis does not mention the use of known pathogenic or benign variants as controls for this assay.",
        "judgment": "No",
        "reasoning": "There is no mention of variant controls, which are necessary to validate functional evidence supporting pathogenicity.",
        "next_step_or_outcome": "Proceed to Step 4"
      },
      {
        "step_name": "Step 4: Apply evidence to individual variant interpretation",
        "extracted_paper_info": "The study focuses on the structural changes in amyloid fibrils [...] without explicit mention of statistical analyses for OddsPath.",
        "judgment": "No",
        "reasoning": "Statistical analyses, particularly OddsPath calculation, were not detailed in the paper.",
        "next_step_or_outcome": "Proceed to Sub-step 4b"
      },
      {
        "step_name": "Sub-step 4b: No OddsPath Calculation",
        "extracted_paper_info": "The total number of variant controls used is not specified in the context provided, so we assume less than 10.",
        "judgment": "Assuming less than 10",
        "reasoning": "Without specific counts, assuming a typical lower threshold for supporting evidence.",
        "final_strength": "Max PS3_supporting"
      }
    ],
    "odds_path_info": {
      "ps3": null,
      "bs3": null
    },
    "finalStrength": {
      "pathogenic": "PS3_supporting",
      "benign": "BS3_supporting"
    }
  }
}